Submission of Notice of 45 Annual General Meeting and Annual Report of the Company for the Financial Year 2025-26

July 31, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Dalal Street, Fort, Bandra Kurla Complex, Bandra East, Mumbai 400 001. Mumbai 400051. Scrip Code: 524774 Symbol: NGLFINE Sub: Regulation 34 – Submission of Notice of 45th Annual General Meeting and Annual Report for the Financial Year 2025-26. Dear Sir/Madam, Pursuant to Regulations 30 and 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Notice convening the 45th Annual General Meeting ("AGM") of NGL Fine-Chem Limited along with the Annual Report of the Company for the Financial Year 2025-26. The 45th AGM of the Company is scheduled to be held on Tuesday, August 25, 2026 at 11:00 A.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM"), in accordance with the applicable provisions of the Companies Act, 2013 and the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The aforesaid Notice and Annual Report are being sent electronically to the Members whose e-mail addresses are registered with the Company/Depositories and are also available on the Company's website at www.nglfinechem.com. Kindly take the same on your record. Thanking you, Yours faithfully, For NGL Fine-Chem Limited Shivam Gharat Company Secretary M. No.: A56704 Encl: As Above. Annual Report 2025-26 Building for the Next Phase of Growth The theme for this year, Building for The Company advanced its CEP, ASMF the Next Phase of Growth, reflects and VMF pipelines, completed validation where the Company stands today. The batches across multiple products. These recovery has restored momentum, and milestones widen the runway for growth the investments made over several and deepen the Company’s relationships years are beginning to translate into a with global animal health customers stronger and more resilient platform. under the China-plus-one sourcing shift. The greenfield expansion at Tarapur Building for the Next Phase of Growth is progressing in phases, with Phase is therefore both a description of I already contributing to operations FY26 and a statement of intent. With a and Phase II positioned to support broader portfolio, expanding regulatory commercial production from the second credentials, growing capacity and an half of FY27. Each step strengthens experienced leadership team, NGL the Company’s ability to serve higher- enters FY27 prepared to convert value, regulated markets. The transition recovery into sustained, long-term towards regulated markets gathered value creation. pace during the year. Forward Looking Statement This document includes forward-looking statements pertaining to anticipated future events and the financial and operational outcomes of NGL Fine-Chem Limited (‘NGL’ or ‘Company’). Given their nature, these forward- looking statements necessitate our Company to make assumptions and are inherently susceptible to risks and uncertainties. There exists a prominent risk that the assumptions, predictions, and other forward-looking statements may not prove to be precise. Readers are advised against placing undue reliance on these forward looking statements, as various factors could lead to disparities between assumptions and actual future results and events. Consequently, this document is subject to a disclaimer and is qualified in entirety by the assumptions, qualifications, and risk factors outlined in our company’s Annual Report. For more info contact us, or visit the website Building for the Inside this report Next Phase Strategic Review Statutory Reports Financial Statements Introducing NGL Fine-Chem Limited Corporate Information 38 Standalone Financials FY26 Highlights 02 Notice 39 Independent Auditor’s Report 117 of Growth About the Company 04 Director’s Report 52 Balance Sheet 127 Product Portfolio 06 Corporate Governance Report 73 Statement of Profit and Loss 128 Our Journey 10 Business Responsibility & 91 Cash Flow Statement 129 Sustainability Report Manufacturing Infrastructure 12 Statement of Changes in Equity 131 Global Presence 14 Notes forming part of Financial 133 Statements Research & Development 16 FY26 marked a year of renewal for NGL Fine-Chem Limited. After three years shaped by pricing pressure, intensifying competition and volatile global trade Performance in Review Consolidated Financials conditions, the Company delivered a broad-based recovery, with growth Key Performance Indicators 18 Independent Auditor’s Report 172 visible across products, geographies and customer segments. Revenue from Letter to Shareholders 20 Balance Sheet 179 Our Strengths 22 operations rose 36% to ₹500.95 crores, EBITDA more than doubled to ₹72.69 Statement of Profit and Loss 180 crores, and profit after tax grew 128% to ₹48.13 crores. The improvement was Commitment to Responsibility Cash Flow Statement 181 led by volume, supported by stronger demand, better capacity utilisation and Board of Directors 24 Statement of Changes in Equity 183 disciplined cost management. Corporate Social Responsibility 26 Notes forming part of Financial 185 Statements Sustainability Initiatives 28 Management Discussion and 30 Analysis Report 2 NGL Fine-Chem Limited Strategic Review Statutory Reports Financial Statements 3 Annual Report 2025-26 FY26 HIGHLIGHTS The Year in Numbers Financial Operational 501 5 ₹ Crores Revenue Manufacturing Facilities 73 20,000 Environmental Governance ₹ Crores m2 EBITDA Total Area of Manufacturing Facilities 4.19 Six Million 48 07 Increment in Green Fuel Adoption No. of Members in the Board ₹ Crores PAT New Products Launched 1,436 Three 537 Fossil Fuel Saved No. of Independent Directors Community Engagement No. of total Employees 65,735 One 41.50 Water Recycled No. of Non-Independent Directors ~₹ Lakhs Total CSR Expenditure R&D Team Strength 481 Two Waste Recycled No. of Women Directors No. of New Initiatives Launched 75% Six 3000 Production From Zero Liquid No. of Board Members with Beneficiaries Discharge Facilities 5+ Years of Experience No. of Lives Benefitted 4 NGL Fine-Chem Limited Strategic Review Statutory Reports Financial Statements 5 Annual Report 2025-26 ABOUT THE COMPANY A Trusted Partner in Strategic Strengths Global Healthcare Dominant Market Share Vertical Integration NGL Fine-Chem Limited (NGL) operates at Quality and Compliance Legacy the intersection of pharmaceutical science, manufacturing precision and healthcare Numerical Callouts Diversified Product Portfolio reliability. Serving both animal and human Global Reach 45 45 health markets, the Company manufactures + Years Sustainability-Led and exports Active Pharmaceutical Ingredients (APIs), advanced intermediates of Manufacturing Excellence Commercial API Manufacturing and finished dosage forms, across global 5 15-50 markets. Over the last four decades, NGL has evolved from being a strong domestic State-of-the-Art Market Share Leadership manufacturer into a globally trusted partner Manufacturing Facilities in Key Products known for process expertise, dependable supply and consistent quality. + 15 Headquartered in Mumbai, the Company operates five Years state-of-the-art GMP certified manufacturing facilities. Customer Served Globally By combining niche chemistry with commercial-scale of Proven Product Reliability execution, the Company excels in complex synthesis, backward integration, and process optimization. This with Zero Market Rejections technical discipline has secured NGL’s leadership in Our Portfolio several veterinary API categories and is driving its strategic expansion into regulated markets. 500 Animal APIs NGL’s recent cleanroom expansions, regulatory filings, + and capacity additions signal a pivot toward higher- Human APIs value opportunities. Even as it scales, the Company Trained Employees remains committed to operational prudence— Intermediates and bal [Showing first 8,000 characters — download PDF for full document]